Literature DB >> 30418203

Association of MRI T2 Signal Intensity With Desmoid Tumor Progression During Active Observation: A Retrospective Cohort Study.

Michael R Cassidy1,2, Robert A Lefkowitz3, Niamh Long3, Li-Xuan Qin4, Amanda Kirane1, Eman Sbaity1, Meera Hameed5, Daniel G Coit1,6, Murray F Brennan1,6, Samuel Singer1,6, Aimeé M Crago1,6.   

Abstract

OBJECTIVE: The aim of this study was to identify predictors of desmoid progression during observation. SUMMARY OF BACKGROUND DATA: Untreated desmoids can grow, remain stable, or regress, but reliable predictors of behavior have not been identified.
METHODS: Primary or recurrent desmoid patients were identified retrospectively from an institutional database. In those managed with active observation who underwent serial magnetic resonance imaging (MRIs) with T2-weighted sequences, baseline tumor size was recorded, and 2 radiologists independently estimated the percentage of tumor volume showing hyperintense T2 signal at baseline. Associations of clinical or radiographic characteristics with progression-free survival (PFS; by RECIST) were evaluated by Cox regression and Kaplan-Meier statistics.
RESULTS: Among 160 patients with desmoids, 72 were managed with observation, and 37 of these had serial MRI available for review. Among these 37 patients, median age was 35 years and median tumor size was 4.7 cm; all tumors were extra-abdominal (41% in abdominal wall). Although PFS was not associated with size, site, or age, it was strongly associated with hyperintense T2 signal in ≥90% versus <90% of baseline tumor volume (as defined by the "test" radiologist; hazard ratio = 11.3, P = 0.003). For patients in the ≥90% group (n = 20), 1-year PFS was 55%, compared with 94% in the <90% group (n = 17). The percentage of baseline tumor volume with hyperintense T2 signal defined by a validation radiologist correlated with results of the test radiologist (ρ = 0.75).
CONCLUSION: The percent tumor volume characterized by hyperintense T2 signal is associated with desmoid progression during observation and may help distinguish patients who would benefit from early intervention from those who may be reliably observed.

Entities:  

Mesh:

Year:  2020        PMID: 30418203      PMCID: PMC6736761          DOI: 10.1097/SLA.0000000000003073

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   13.787


  21 in total

1.  Activity of Sorafenib against desmoid tumor/deep fibromatosis.

Authors:  Mrinal M Gounder; Robert A Lefkowitz; Mary Louise Keohan; David R D'Adamo; Meera Hameed; Cristina R Antonescu; Samuel Singer; Katherine Stout; Linda Ahn; Robert G Maki
Journal:  Clin Cancer Res       Date:  2011-03-29       Impact factor: 12.531

2.  The enigma of desmoid tumors.

Authors:  J J Lewis; P J Boland; D H Leung; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

3.  Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor).

Authors:  Veridiana Pires de Camargo; Mary L Keohan; David R D'Adamo; Cristina R Antonescu; Murray F Brennan; Samuel Singer; Linda S Ahn; Robert G Maki
Journal:  Cancer       Date:  2010-05-01       Impact factor: 6.860

4.  Recent trends in the management of desmoid tumors. Summary of 19 cases and review of the literature.

Authors:  D W Easter; N A Halasz
Journal:  Ann Surg       Date:  1989-12       Impact factor: 12.969

5.  Problems in diagnosis and management of desmoid tumors.

Authors:  R Lopez; N Kemalyan; H S Moseley; D Dennis; R M Vetto
Journal:  Am J Surg       Date:  1990-05       Impact factor: 2.565

6.  New concepts in understanding evolution of desmoid tumors: MR imaging of 30 lesions.

Authors:  J E Vandevenne; A M De Schepper; L De Beuckeleer; E Van Marck; F Aparisi; J L Bloem; Z Erkorkmaz; S Brijs
Journal:  Eur Radiol       Date:  1997       Impact factor: 5.315

7.  Desmoid fibromatosis is a clonal process.

Authors:  M Li; C Cordon-Cardo; W L Gerald; J Rosai
Journal:  Hum Pathol       Date:  1996-09       Impact factor: 3.466

8.  Extra-abdominal desmoid tumors.

Authors:  M G Rock; D J Pritchard; H M Reiman; E H Soule; R C Brewster
Journal:  J Bone Joint Surg Am       Date:  1984-12       Impact factor: 5.284

9.  Toward Observation as First-line Management in Abdominal Desmoid Tumors.

Authors:  Sally M Burtenshaw; Amanda J Cannell; Edward D McAlister; Saquib Siddique; Rita Kandel; Martin E Blackstein; Carol J Swallow; Rebecca A Gladdy
Journal:  Ann Surg Oncol       Date:  2016-03-28       Impact factor: 5.344

10.  Extra-abdominal desmoid tumors.

Authors:  G Markhede; L Lundgren; N Bjurstam; O Berlin; B Stener
Journal:  Acta Orthop Scand       Date:  1986-02
View more
  11 in total

1.  Pseudoaneurysm within a desmoid tumor in an extremity: report of 2 cases.

Authors:  Niamh M Long; Mrinal M Gounder; Aimee M Crago; Alexander J Chou; David M Panicek
Journal:  Skeletal Radiol       Date:  2021-03-16       Impact factor: 2.199

2.  Evidence-based MR imaging follow-up strategy for desmoid-type fibromatosis.

Authors:  P A Gondim Teixeira; H Biouichi; W Abou Arab; M Rios; F Sirveaux; G Hossu; A Blum
Journal:  Eur Radiol       Date:  2019-08-29       Impact factor: 5.315

3.  The Clinical Features of Multicentric Extra-abdominal Desmoid Tumors.

Authors:  Yusuke Minami; Seiichi Matsumoto; Keisuke Ae; Taisuke Tanizawa; Keiko Hayakawa; Masanori Saito; Norio Kurosawa
Journal:  Cancer Diagn Progn       Date:  2021-07-03

4.  Retroperitoneal desmoid tumor in a patient with familial adenomatous polyposis: A case report.

Authors:  Fathia Aidid; Narjisse Aichouni; Ihssane Afilal; Widad Abbou; Rachid Jabi; Nadir Miry; Amal Bennani; Imane Kamaoui; Siham Nasri; Imane Skiker
Journal:  Radiol Case Rep       Date:  2022-06-17

5.  CRISPR-SID: Identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping.

Authors:  Thomas Naert; Dieter Tulkens; Tom Van Nieuwenhuysen; Joanna Przybyl; Suzan Demuynck; Matt van de Rijn; Mushriq Al-Jazrawe; Benjamin A Alman; Paul J Coucke; Kim De Leeneer; Christian Vanhove; Savvas N Savvides; David Creytens; Kris Vleminckx
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-23       Impact factor: 12.779

6.  Upfront surgery is not advantageous compared to more conservative treatments such as observation or medical treatment for patients with desmoid tumors.

Authors:  Shinji Tsukamoto; Piergiuseppe Tanzi; Andreas F Mavrogenis; Manabu Akahane; Akira Kido; Yasuhito Tanaka; Marilena Cesari; Davide Maria Donati; Alessandra Longhi; Costantino Errani
Journal:  BMC Musculoskelet Disord       Date:  2021-01-05       Impact factor: 2.362

7.  MRI T1 Contrast-Enhanced Signal Intensity Is a Prognostic Indicator of Imatinib Therapy in Desmoid-Type Fibromatosis.

Authors:  Hui Ci Zhu; Shi Xing Xu; Xiao Ting Li; Zhen Guan; Shu Li; Ying-Shi Sun
Journal:  Front Oncol       Date:  2021-03-15       Impact factor: 6.244

8.  Efficacy and safety of cyclooxygenase 2 inhibitors for desmoid tumor management: a systematic review.

Authors:  Makoto Emori; Yoshihiro Matsumoto; Yasutaka Murahashi; Masahiro Yoshida; Yoshihiro Nishida
Journal:  Nagoya J Med Sci       Date:  2021-11       Impact factor: 1.131

9.  Clinical Characteristics and Treatment of Intra-abdominal Aggressive Fibromatosis: A Retrospective Study of 16 Patients.

Authors:  Jianchun Xiao; Jinzhu Mao; Binglu Li
Journal:  Front Med (Lausanne)       Date:  2020-01-31

10.  Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid-type fibromatosis.

Authors:  Edoardo Zanchetta; Chiara Maura Ciniselli; Annalisa Bardelli; Chiara Colombo; Silvia Stacchiotti; Giacomo Giulio Baldi; Salvatore Provenzano; Rossella Bertulli; Federica Bini; Alessandra Casale; Francesca Gabriella Greco; Andrea Ferrari; Paolo Verderio; Marco Fiore; Alessandro Gronchi; Paolo Giovanni Casali; Carlo Morosi; Elena Palassini
Journal:  Cancer Med       Date:  2021-06-08       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.